News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Okta (OKTA) could deliver about 2 percentage points of upside to the midpoint of its fiscal Q2 2027 revenue guidance as sales execution improves and demand strengthens across its identity products, Oppenheimer said in a report Tuesday.The firm cited "above plan" partner checks, Silver …
Sharemaestro market context Trend signal active 52 weeks +51.9% · Next-week setup negative 28.5%The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though? Let's …
Sharemaestro market context Trend signal active 52 weeks +51.9% · Next-week setup negative 28.5%Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Nektar Therapeutics (NKTR) on behalf of investors who purchased securities before February 26, 2025, and still hold them. The investigation aims to determine if Nektar's officers and/or directors engaged in corporate wrongdoing. The firm …
Kuehn Law is investigating Nektar Therapeutics over allegations that the company misled shareholders regarding the integrity of its REZOLVE-AA clinical trial. The lawsuit claims Nektar Therapeutics failed to adhere to trial protocols, overstated the trial's validity, and made false public statements. This could negatively …
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Nektar Therapeutics (NASDAQ:NKTR). The investigation concerns whether Nektar and certain officers engaged in corporate wrongdoing. Investors who purchased Nektar securities prior to February 26, 2025, and continue to hold them, …
This article lists numerous Exchange Traded Funds (ETFs) that hold Okta, Inc. Class A stocks, providing key financial data for each. The funds are sorted by market value and include details such as weight in the ETF, issuer, management style, focus, expense ratio, AUM, …
Okta stock has surged over 70% in 2026 as AI-based "agents" that perform tasks on the internet require new cybersecurity safeguards. Continue Reading
Sharemaestro market context Trend signal active 52 weeks +51.9% · Next-week setup negative 28.5%FMR LLC has filed an Amendment No. 7 to Schedule 13G/A, disclosing a significant ownership stake in Okta Inc. Class A common stock. The filing indicates beneficial ownership of 19,294,277.37 shares, representing 11.6% of the class as of July 31, 2026. Abigail P. Johnson …
Okta (OKTA) closed the most recent trading day at $143.51, moving -2.4% from the previous trading session. The stock's performance was behind the S&P 500's daily loss of 0.18%. At the same time, the Dow lost 0.85%, and the tech-heavy Nasdaq lost 0.06%. The …
Sharemaestro market context Trend signal active 52 weeks +51.9% · Next-week setup negative 28.5%CCORF has reiterated its Buy rating on Nektar Therapeutics (NKTR.US) and maintained its target price at $153. This indicates a continued positive outlook from the firm regarding the company's stock performance and potential.
FMR LLC and Abigail P. Johnson have disclosed a 9.8% beneficial ownership stake in Okta (OKTA) Class A common stock, totaling 16,272,067.75 shares. The filing, an amended Schedule 13G, indicates FMR LLC holds sole voting power over 15,839,664.30 shares and sole dispositive power over …
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Okta stock has delivered strong gains over the last three years, yet the current checks point to shares that do not screen as …
Sharemaestro market context Trend signal active 52 weeks +51.9% · Next-week setup negative 28.5%Nektar Therapeutics has initiated two global Phase 3 trials, ZENITH AD‑1 and ZENITH AD‑2, for its drug rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis. This development is seen as a crucial step for the company, potentially reshaping its investment narrative by providing a near-term …
Bronstein, Gewirtz & Grossman, LLC has announced an investigation into Nektar Therapeutics (NKTR) regarding potential corporate wrongdoing by its officers and directors. The firm is encouraging investors who purchased Nektar securities before February 26, 2025, and still hold them, to join the investigation. Bronstein, …
Okta, Inc. (NASDAQ:OKTA) is set to release its Q2 FY2027 earnings on August 26, 2026, after the U.S. market closes. Concurrently, reports indicate that Okta is acquiring the AI security startup Permiso for approximately $200 million, a move that analysts suggest could significantly impact …
Okta has signed a definitive agreement to acquire Permiso Security, a cloud-native identity security platform that detects and mitigates threats across human, non-human, and AI agent identities in multi-cloud environments. The deal, valued at roughly $200 million in an almost all-cash transaction per TechCrunch …
Sharemaestro market context Trend signal active 52 weeks +51.9% · Next-week setup negative 28.5%SAN FRANCISCO, August 01, 2026--(BUSINESS WIRE)--Okta, Inc. (NASDAQ: OKTA), the leading independent identity partner, today announced that it will release its financial results for its second quarter fiscal year 2027 ended July 31, 2026 after the U.S. market close on Wednesday, August 26, 2026. …
Sharemaestro market context Trend signal active 52 weeks +51.9% · Next-week setup negative 28.5%This article presents financial data for Nektar Therapeutics (NASDAQ: NKTR), specifically focusing on its enterprise value to EBIT forward. The data is provided by TradingView, indicating that the market for NKTR was closed at the time of publication with no trades. The content highlights …
Vanguard Capital Management has reported a beneficial ownership of 5.17% in Nektar Therapeutics (NKTR) common stock as of June 30, 2026. This stake, totaling 1,747,653 shares, includes holdings in Vanguard funds and managed accounts. Vanguard exercises sole voting power over 250,804 shares and sole …
In the latest close session, Okta (OKTA) was up +2.56% at $140.42. This move outpaced the S&P 500's daily gain of 1.66%. At the same time, the Dow added 1.19%, and the tech-heavy Nasdaq gained 2.78%. Coming into today, shares of the cloud identity …
Sharemaestro market context Trend signal active 52 weeks +51.9% · Next-week setup negative 28.5%Okta on Thursday agreed to acquire AI identity security startup Permiso Security, betting that demand for protecting AI agents and other machine identities will grow as enterprises deploy autonomous software across their operations. The identity management company did not disclose the terms of the …
Sharemaestro market context Trend signal active 52 weeks +51.9% · Next-week setup negative 28.5%BlackRock, Inc. has disclosed a 7.8% beneficial ownership stake in Nektar Therapeutics (NKTR), amounting to 2,643,796 shares of common stock as of June 30, 2026. This ownership was reported via a Schedule 13G filing, indicating that BlackRock holds sole voting power over 2,590,855 shares …
Nektar Therapeutics will announce its second-quarter financial results on Thursday, August 13, 2026, after the close of U.S.-based financial markets. President and CEO Howard Robin will host a conference call at 5:00 p.m. ET/2:00 p.m. PT to discuss the results. An audio-only webcast will …
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2026, on Thursday, August 13, 2026, after the close of U.S. financial markets. CEO Howard Robin will host a conference call at 5:00 p.m. ET / 2:00 p.m. …
Search by ticker symbol or company name and select a result to open its chart.